Susceptibility of Major Pathogens - 1998
Institutional Antibiotic Control Program

Notes
Antibiotic Classes
Back to Reference Page

	Gram Positive								Gram Negative
Total Isolates (1998)1	1343	1345	1150	323	912	146	1012	1962	66	1421	871	95	468	113	266	148	851	117	321	43
Amikacin										100	78	100	94	97	99	94	90	4	70
Ampicillin	5	8	99	15			77	86	59	54	0	0	0	12	84	0
Ampicillin/Sulbactam	54	36							93	58	53	76	19	56	89	3			90	93
Aztreonam										98	69	93	56	73	97	86	68	3	5
Cefazolin	54	36					77	97		91	62	65	3	2	90	0
Cefoxitin										95	77	96	5	5	98	16				91
Ceftazidime										98	69	96	53	72	98	87	83	29	22
Ceftriaxone							87		93	99	73	95	55	75	99	94	20	0	16
Cefuroxime									96
Chloramphenicol	97	92	77	97			93	99	90	85	58	92	60	75	89	19		38	3	93
Ciprofloxacin	52	45	56	7					100	93	69	96	80	87	95	79	71	21	23
Clindamycin	56	52			93	88	90	91												78
Co-Trimoxazole3	84	59					71		81	77	63	80	78	78	92	92	6	94	39
Erythromycin	38	26			91	72	79	73
Gentamicin	67	58	704	324						93	66	97	80	88	91	94	71	5	22
Imipenem/Cilastatin										100	99	100	98	99	98	98	79	0	73
Metronidazole																				93
Nafcillin	54	36
Penicillin	5	8			100	100	77	86												7
Piperacillin/Tazobactam										81	60	80	60	73	79	75	67	42	30	745
Tetracycline			31	50			84	72
Ticarcillin/Clavulanate	54	36								88	64	93	51	71	100	90	81	44	26
Tobramycin										95	66	98	82	92	92	89	90	5	38
Vancomycin	100	1006	95	23	100	100	100	100

Notes:

1. Percent susceptibility includes duplicate isolates from same patient.
2. Includes both inpatients and outpatients.
3. Co-Trimoxazole is Sulfamethoxazole plus Trimethoprim.
4. Gentamicin synergy.
5. Bacteroides were tested against piperacillln; percent susceptible to piperacillin / tazobactam may be higher.
6. Includes 1 vancomycin-intermediate strain of S. haemolyticus.

Original page created with permission: October 14, 1998

Created: October 14, 1998 Edited: October 3, 2000.
Copyright © 1998-2001.